Enovis Corp

Equity Share Repurchase Program In 2018, the Company s Board of Directors authorized the repurchase of shares of the Company s Common stock from time-to-time on the open market or in privately negotiated transactions.

SEC original ↗Enovis Corp — 10-Q Quarterly report10-QAug 6, 2026

No repurchases of the Company s Common stock have been made under this plan since the third quarter of 2018.

SEC original ↗Enovis Corp — 10-Q Quarterly report10-QAug 6, 2026

As of July 3, 2026, the remaining stock repurchase authorization provided by the Board of Directors was $ 100 million.

SEC original ↗Enovis Corp — 10-Q Quarterly report10-QAug 6, 2026

The timing, amount and method of shares repurchased is determined by management based on its evaluation of market conditions and other factors.

SEC original ↗Enovis Corp — 10-Q Quarterly report10-QAug 6, 2026

There is no term associated with the remaining repurchase authorization.

SEC original ↗Enovis Corp — 10-Q Quarterly report10-QAug 6, 2026

All facilities under the Enovis Credit Agreement (including the Term Loan) are guaranteed and secured by certain personal property of the Company and certain of its subsidiaries, subject to limitations and exclusions.

SEC original ↗Enovis Corp — 10-Q Quarterly report10-QAug 6, 2026

Realizing this potential will require continued operational discipline and a sharp focus on scalable, capital efficient execution.

SEC original ↗Enovis Corp — Earnings release (8-K exhibit)EX-99Aug 7, 2025

We are in the early stages of unlocking the full value of our orthopedic platform, and I m excited to lead the Company with a commitment to continue helping millions of people lead full, active lives with a focus on creating shareholder value.

SEC original ↗Enovis Corp — Earnings release (8-K exhibit)EX-99Aug 7, 2025

I m grateful to the Board and the entire Enovis team for their support and alignment on our strategy.

SEC original ↗Enovis Corp — Earnings release (8-K exhibit)EX-99Aug 7, 2025

Adjusted net income and Adjusted net income per diluted share exclude net income attributable to noncontrolling interest from continuing operations, net of taxes the effect of Loss from discontinued operations, net of taxes restructuring charges Medical Device Regulation ( MDR ) fees and other costs strategic transaction costs stock-based compensation acquisition-related intangible asset amortization strategic purchase of economic interest on future royalty payments property plant and equipment step-up depreciation, and fair value charges on acquired inventory Other (income) expense, net and include the tax effect of adjusted pre-tax income at applicable tax rates and other tax adjustments.

SEC original ↗Enovis Corp — Earnings release (8-K exhibit)EX-99Aug 7, 2025

(6) In the first and second quarters of 2025, we completed strategic purchases of economic interest on future royalty payments in our intellectual property ( royalty interest ) for a fixed price of $56.5 million, which will be paid over nine years.

SEC original ↗Enovis Corp — Earnings release (8-K exhibit)EX-99Aug 7, 2025

Forward-looking statements are based on Enovis current expectations and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such forward-looking statements.

SEC original ↗Enovis Corp — Earnings release (8-K exhibit)EX-99Aug 7, 2025

Enovis does not provide reconciliations of adjusted EBITDA or adjusted earnings per share on a forward-looking basis to the closest GAAP financial measures, as such information is not available without unreasonable efforts on a forward-looking basis due to uncertainties regarding, and the potential variability of, reconciling items excluded from these measures.

SEC original ↗Enovis Corp — Earnings release (8-K exhibit)EX-99Aug 7, 2025

Legal Proceedings 43 Item 1A.

SEC original ↗Enovis Corp — 10-Q Quarterly report10-QAug 6, 2026

A change in these unobservable inputs to a different amount might result in a significantly higher or lower fair value measurement at the reporting date due to the nature of uncertainty inherent to the estimates.

SEC original ↗Enovis Corp — 10-Q Quarterly report10-QAug 6, 2026

For further description of the Company s litigation and contingencies, reference is made to Note 18, Commitments and Contingencies in the Notes to Consolidated Financial Statements in the Company s 2025 Form 10-K.

SEC original ↗Enovis Corp — 10-Q Quarterly report10-QAug 6, 2026